Technical Reports on Medical Equipment Equities -- Lantheus, Nevro, Steris, and Spectranetics

Monday, November 21, 2016 Medical Gadgets
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, November 21, 2016 /PRNewswire/ -- redirects investors' attention to the Medical Appliances

and Equipment industry which is engaged in the manufacture of medical instruments such as dental and surgical appliances. Companies to assess are: Lantheus Holdings Inc. (NASDAQ: LNTH), Nevro Corp. (NYSE: NVRO), Steris PLC (NYSE: STE), and The Spectranetics
Corp. (NASDAQ: SPNC). These equities belong to the Healthcare sector which was mixed in pre-market trade on Friday, November 18, 2016. Today's research reports on the aforementioned stocks are downloadable for free upon registration at:


Last Friday, Massachusetts headquartered Lantheus Holdings Inc.'s stock closed the day flat at $9.25 with a total trading volume of 346,044 shares. The Company's shares have advanced 12.94% in the previous three months and 173.67% on an YTD basis. The stock is trading 7.32% above its 50-day moving average and 95.43% above its 200-day moving average. Additionally, shares of Lantheus, which develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide, have a Relative Strength Index (RSI) of 50.80.

On November 8th, 2016, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $6 a share to $12 a share.

On November 15th, 2016, Lantheus announced an agreement to sell 3,000,000 shares of its common stock. The offering is expected to consist of 1,000,000 shares to be offered by the Company and 2,000,000 shares to be offered by certain of its existing stockholders. The Company intends to use a combination of net proceeds from this offering, together with cash on hand, to repay approximately $20 million of the outstanding principal balance under its senior secured credit facilities. The Company will not receive any proceeds from the sale of shares by the selling stockholders. Visit us today and access our complete research report on LNTH at:


Shares in California headquartered Nevro Corp. rose 1.43%, finishing the session at $89.55. The stock recorded a trading volume of 369,401 shares. The Company's shares have gained 32.65% since the start of this year. The stock is trading above its 200-day moving average by 16.49%. Furthermore, shares of Nevro, which develops and commercializes a neuromodulation platform for the treatment of chronic pain in the US, Europe, and Australia, have an RSI of 48.50.

On November 8th, 2016, Nevro announced that it achieved revenue of $60.9 million in Q3 2016, an increase of 296% as reported, over Q3 2015. Gross profit for Q3 2016 was $41.7 million, representing a 68% of gross margin, up from $9.4 million, representing a 61% of gross margin, in Q3 2015. The company recorded loss from operations for Q3 2016 of $1.9 million compared to $17.7 million for Q3 2015. The complimentary report on NVRO can be downloaded at:


UK-based Steris PLC's stock finished 0.29% lower at $66.22 with a total trading volume of 381,679 shares. Shares of the Company, which develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide, are trading below their 200-day moving average by 3.93%. The stock has an RSI of 41.19.

As per notes filed with the SEC on November 8th, 2016, STERIS identified certain errors in its Consolidated Condensed Statement of Cash Flows and related calculation of Free Cash Flow for the six months ended September 30th, 2016, which were originally published with the Company's Q2 FY17 financial results on November 2nd, 2016. As originally published, net cash provided by operating activities, net cash used in investing activities, and net cash used in financing activities were $182.5 million, $13.3 million, and $151.1 million, respectively. After corrections, net cash provided by operating activities, net cash used in investing activities, and net cash used in financing activities were $188.5 million, $8.7 million and $161.6 million, respectively. Free cash flow as originally published was $108.9 million and is now $119.4 million. Register for free on and access the latest research report on STE at:

The Spectranetics

Shares in Colorado Springs, Colorado headquartered The Spectranetics Corp. ended last Friday's session 1.49% higher at $23.80 and with a total trading volume of 356,023 shares. The stock has advanced 58.03% on an YTD basis. The Company's shares are trading 0.78% above their 50-day moving average and 20.97% above their 200-day moving average. Moreover, shares of Spectranetics, which together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system, have an RSI of 55.67.

On October 21st, 2016, research firm Needham reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $27 a share to $32 a share. Get free access to your research report on SPNC at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store